Spatial Omics for Personalized Kidney Disease Care

Abstract

Spatial omics technologies are revolutionizing the understanding and management of kidney diseases by enabling spatially resolved, high-resolution profiling of transcriptomes, proteomes, and metabolomes within renal tissue microenvironments. This review discusses the epidemiological significance of kidney diseases, underlying pathophysiological mechanisms, and how spatial omics provides unprecedented insight into intrarenal heterogeneity, cellular interactions, and molecular signatures. Emphasis is placed on the clinical implications of spatial omics for risk stratification, diagnosis, and the development of targeted, personalized therapies, as well as recent advances, emerging applications, and current guideline recommendations for integrating spatial omics into kidney disease care.

Introduction

Kidney diseases encompass a spectrum of disorders with significant morbidity and mortality worldwide. Traditional diagnostic and therapeutic strategies often fail to account for the complex, heterogeneous nature of renal pathology at the tissue and cellular level. The recent emergence of spatial omics integrating spatial transcriptomics, proteomics, and metabolomics provides a multidimensional view of renal tissue architecture and molecular landscapes. These technologies enable clinicians and researchers to map disease processes with unprecedented detail, offering the promise of individualized diagnosis and treatment. This review critically examines the role of spatial omics in transforming the clinical approach to kidney disease, highlights current evidence, and explores future directions in the context of personalized nephrology.

Epidemiology / Disease Burden

Chronic kidney disease (CKD) affects approximately 10% of the global population, with rising incidence and substantial healthcare costs. Acute kidney injury (AKI) and various glomerular and tubulointerstitial diseases further contribute to the burden, disproportionately impacting vulnerable populations. Mortality rates are high, particularly in advanced CKD and end-stage kidney disease (ESKD). The heterogeneity of disease etiologies and variable clinical courses underscore the need for precise molecular characterization to inform effective interventions. Spatial omics offers a powerful tool to dissect the diverse cellular and molecular underpinnings of kidney pathology, facilitating improved epidemiological understanding and resource allocation.

Pathophysiology

Kidney disease pathogenesis involves complex interactions between genetic, epigenetic, and environmental factors, leading to alterations in cellular phenotypes, intercellular communication, immune infiltration, and fibrotic remodeling. Spatial omics elucidates the spatial distribution of gene and protein expression within distinct renal compartments, such as the glomerulus, tubules, interstitium, and vasculature. For example, spatial transcriptomics has revealed unique patterns of immune cell localization and activation in lupus nephritis and diabetic nephropathy, offering mechanistic insights into tissue-specific injury and repair processes. Understanding the spatial context of pathogenic processes is critical for developing targeted interventions and monitoring therapeutic responses.

Risk Factors

Traditional risk factors for kidney disease include hypertension, diabetes mellitus, autoimmune disorders, genetic predispositions, and environmental exposures. However, the interplay of these factors at the tissue level is not fully captured by conventional approaches. Spatial omics enables the identification of microenvironmental risk signatures, such as localized proinflammatory or profibrotic niches, that may confer increased susceptibility to disease progression or therapeutic resistance. Integrating spatial omics data with clinical risk models may enhance the early detection and prevention of high-risk kidney disease phenotypes.

Clinical Features

Kidney diseases present with a broad range of clinical manifestations, from asymptomatic biochemical abnormalities to nephrotic syndrome, hematuria, rapidly progressive glomerulonephritis, and chronic renal insufficiency. The spatial heterogeneity of molecular alterations often correlates with focal or segmental patterns of histopathology and clinical severity. Spatial omics refines the interpretation of clinical features by linking them to specific molecular and cellular events within renal tissue, enabling more precise phenotyping and prognostication.

Diagnosis

Renal biopsy remains the gold standard for diagnosing kidney diseases, but conventional histopathology offers limited molecular resolution. Spatial omics overcomes these limitations by providing high-dimensional molecular maps of renal tissue, enabling the detection of subtle pathologic alterations, molecular subtypes, and disease trajectories. Spatial transcriptomics, in particular, distinguishes active inflammatory lesions from chronic fibrotic damage and identifies early molecular changes preceding histologic injury. These capabilities can improve diagnostic accuracy, guide therapeutic decisions, and facilitate noninvasive biomarker discovery through the correlation of tissue and liquid biopsy profiles.

Treatment & Management

Current treatment strategies for kidney diseases often rely on broad immunosuppression, renin-angiotensin system blockade, glycemic control, and supportive measures. Spatial omics refines therapeutic targeting by identifying disease-driving cell populations, signaling pathways, and spatially restricted molecular networks. This approach supports the development of personalized therapies tailored to the unique molecular landscape of each patient's kidney disease. Spatial omics data can also inform the selection of patients most likely to benefit from specific interventions and monitor therapeutic efficacy at the tissue level, facilitating adaptive management strategies.

Recent Advances / Emerging Therapies

Recent advances in spatial omics technologies include the integration of multiplexed imaging, single-cell RNA sequencing, and proteomic mapping, enabling comprehensive characterization of renal tissue at subcellular resolution. These innovations have led to the identification of novel therapeutic targets, such as specific immune cell subsets and profibrotic signaling nodes, and the discovery of spatial biomarkers predictive of treatment response or disease progression. Clinical trials are increasingly incorporating spatial omics endpoints to evaluate the efficacy of emerging therapies, including cell-based interventions, targeted biologics, and small-molecule inhibitors. The translation of these advances into clinical practice is accelerating the shift toward precision nephrology.

Guideline Recommendations

Leading nephrology organizations and expert consensus panels are beginning to recognize the clinical utility of spatial omics in kidney disease care. While routine integration into clinical workflows is not yet standard, guidelines increasingly recommend the use of advanced molecular diagnostics for challenging or atypical cases, research protocols, and biomarker development. Ongoing studies are expected to inform evidence-based guidelines for the use of spatial omics in risk stratification, diagnosis, and treatment selection. Multidisciplinary collaboration among nephrologists, pathologists, and translational scientists is essential to realize the full potential of spatial omics in clinical practice.

Conclusion

Spatial omics represents a paradigm shift in the personalized care of kidney disease, offering unprecedented insights into the spatial and molecular complexity of renal pathology. By enabling high-resolution mapping of disease mechanisms and therapeutic targets within renal tissues, spatial omics promises to transform diagnosis, risk assessment, and individualized treatment strategies. Continued technological refinement, clinical validation, and integration into evidence-based guidelines will be crucial to harnessing the full clinical impact of spatial omics in nephrology.